Daniel J. Crona

1.9k total citations · 1 hit paper
51 papers, 1.2k citations indexed

About

Daniel J. Crona is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Daniel J. Crona has authored 51 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Pulmonary and Respiratory Medicine, 15 papers in Molecular Biology and 12 papers in Oncology. Recurrent topics in Daniel J. Crona's work include Prostate Cancer Treatment and Research (6 papers), Pharmacogenetics and Drug Metabolism (5 papers) and Radiopharmaceutical Chemistry and Applications (4 papers). Daniel J. Crona is often cited by papers focused on Prostate Cancer Treatment and Research (6 papers), Pharmacogenetics and Drug Metabolism (5 papers) and Radiopharmaceutical Chemistry and Applications (4 papers). Daniel J. Crona collaborates with scholars based in United States, Finland and United Kingdom. Daniel J. Crona's co-authors include Young E. Whang, Matthew I. Milowsky, Matthew D. Galsky, Aimee Faso, Kathleen A. McGraw, Tomohiro F. Nishijima, James West, Julie W. Harral, Christine M. Walko and Susan M. Majka and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Daniel J. Crona

48 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Systematic Review of Strategies to Prevent Cisplatin-Induced Nephrotoxicity

2017 288 citations Daniel J. Crona, Matthew I. Milowsky et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Daniel J. Crona United States	17	494	350	248	196	133	51	1.2k
Michael A. Tortorici United States	21	507 1.0×	457 1.3×	538 2.2×	129 0.7×	205 1.5×	69	1.9k
Brian K. Rivera United States	23	369 0.7×	443 1.3×	224 0.9×	128 0.7×	198 1.5×	52	1.5k
Leni van Doorn Netherlands	18	430 0.9×	540 1.5×	537 2.2×	111 0.6×	126 0.9×	56	1.2k
Olivier Huillard France	20	438 0.9×	311 0.9×	540 2.2×	61 0.3×	141 1.1×	84	1.4k
Luigi Rossi Italy	20	332 0.7×	400 1.1×	342 1.4×	180 0.9×	219 1.6×	58	1.5k
Antonella Brunello Italy	23	474 1.0×	354 1.0×	907 3.7×	138 0.7×	252 1.9×	119	1.8k
Daniel R. Saltzstein United States	20	654 1.3×	243 0.7×	219 0.9×	91 0.5×	163 1.2×	87	2.0k
Rakesh Goel Canada	20	287 0.6×	376 1.1×	790 3.2×	244 1.2×	134 1.0×	95	1.5k
Craig Eagle United States	13	239 0.5×	254 0.7×	536 2.2×	240 1.2×	299 2.2×	26	1.6k
Stijn L.W. Koolen Netherlands	25	755 1.5×	545 1.6×	1.1k 4.4×	108 0.6×	253 1.9×	155	2.3k

Countries citing papers authored by Daniel J. Crona

Since Specialization

Citations

This map shows the geographic impact of Daniel J. Crona's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel J. Crona with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel J. Crona more than expected).

Fields of papers citing papers by Daniel J. Crona

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel J. Crona. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel J. Crona. The network helps show where Daniel J. Crona may publish in the future.

Co-authorship network of co-authors of Daniel J. Crona

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel J. Crona. A scholar is included among the top collaborators of Daniel J. Crona based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel J. Crona. Daniel J. Crona is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Crona, Daniel J., Bhadran Bose, Patrick H. Nachman, et al.. (2024). Anticoagulation for the Prevention of Thrombotic Events in Nephrotic Syndrome. Kidney International Reports. 9(10). 3053–3056. 2 indexed citations

Laitinen, Tuomo, et al.. (2022). Optimization of the 4-anilinoquin(az)oline scaffold as epidermal growth factor receptor (EGFR) inhibitors for chordoma utilizing a toxicology profiling assay platform. Scientific Reports. 12(1). 12820–12820. 6 indexed citations

Quintanilha, Júlia C.F., Susan M. Geyer, Amy S. Etheridge, et al.. (2022). KDR genetic predictor of toxicities induced by sorafenib and regorafenib. The Pharmacogenomics Journal. 22(5-6). 251–257. 5 indexed citations

Austin, Charles, et al.. (2022). The Pharmacogenetics of Opiates and Its Impact on Delirium in Mechanically Ventilated Adults: A Pilot Study. Journal of Pharmacy Technology. 38(4). 195–201.

Quintanilha, Júlia C.F., Alessandro Racioppi, Jin Wang, et al.. (2021). PIK3R5 genetic predictors of hypertension induced by VEGF-pathway inhibitors. The Pharmacogenomics Journal. 22(1). 82–88. 6 indexed citations

Dunn, Mary, Amir H. Khandani, Paul A. Godley, et al.. (2021). A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer. PLoS ONE. 16(6). e0253021–e0253021. 5 indexed citations

Koyioni, Maria, Chad Torrice, William A. Murphy, et al.. (2021). Design and evaluation of 1,2,3-dithiazoles and fused 1,2,4-dithiazines as anti-cancer agents. Bioorganic & Medicinal Chemistry Letters. 43. 128078–128078. 7 indexed citations

Asquith, Christopher R. M., et al.. (2019). Anti-tubercular activity of novel 4-anilinoquinolines and 4-anilinoquinazolines. Bioorganic & Medicinal Chemistry Letters. 29(18). 2695–2699. 19 indexed citations

Innocenti, Federico, Chen Jiang, Alexander B. Sibley, et al.. (2019). An initial genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients in CALGB 80303 (Alliance). Pharmacogenetics and Genomics. 29(6). 123–131. 5 indexed citations

10.

Valgus, John, Kristin Weitzel, Josh F. Peterson, Daniel J. Crona, & Christine M. Formea. (2019). Current practices in the delivery of pharmacogenomics: Impact of the recommendations of the Pharmacy Practice Model Summit. American Journal of Health-System Pharmacy. 76(8). 521–529. 7 indexed citations

11.

Crona, Daniel J., Andrew D. Skol, Veli‐Matti Leppänen, et al.. (2018). Genetic Variants of VEGFA and FLT4 Are Determinants of Survival in Renal Cell Carcinoma Patients Treated with Sorafenib. Cancer Research. 79(1). 231–241. 25 indexed citations

12.

Moll, Stephan, Daniel J. Crona, & Karlyn A. Martin. (2018). Direct oral anticoagulants in extremely obese patients: OK to use?. Research and Practice in Thrombosis and Haemostasis. 3(2). 152–155. 27 indexed citations

13.

Reynolds, Monica L., Patrick H. Nachman, Micah J. Mooberry, Daniel J. Crona, & Vimal K. Derebail. (2018). Recurrent venous thromboembolism in primary membranous nephropathy despite direct Xa inhibitor therapy. Journal of Nephrology. 32(4). 669–672. 18 indexed citations

14.

Glubb, Dylan M., Laia Paré, Eloísa Jantus‐Lewintre, et al.. (2015). Functional FLT1 Genetic Variation is a Prognostic Factor for Recurrence in Stage I–III Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology. 10(7). 1067–1075. 15 indexed citations

15.

Crona, Daniel J., Jacqueline Ramı́rez, Wei Qiao, et al.. (2015). Clinical validity of new genetic biomarkers of irinotecan neutropenia: an independent replication study. The Pharmacogenomics Journal. 16(1). 54–59. 16 indexed citations

16.

Crona, Daniel J. & Young E. Whang. (2014). Posterior reversible encephalopathy syndrome induced by enzalutamide in a patient with castration-resistant prostate cancer. Investigational New Drugs. 33(3). 751–754. 13 indexed citations

17.

Majka, Susan M., Moira Hagen, Thomas R. Blackwell, et al.. (2011). Physiologic and molecular consequences of endothelial Bmpr2 mutation. Respiratory Research. 12(1). 84–84. 51 indexed citations

18.

Crona, Daniel J., Julie W. Harral, Serge Adnot, Saadia Eddahibi, & James West. (2009). Gene expression in lungs of mice lacking the 5-hydroxytryptamine transporter gene. BMC Pulmonary Medicine. 9(1). 19–19. 13 indexed citations

19.

West, James, Julie W. Harral, Kirk B. Lane, et al.. (2008). Mice expressing BMPR2^R899X transgene in smooth muscle develop pulmonary vascular lesions. American Journal of Physiology-Lung Cellular and Molecular Physiology. 295(5). L744–L755. 112 indexed citations

20.

Tada, Yuji, Susan M. Majka, Michele M. Carr, et al.. (2007). Molecular effects of loss of BMPR2 signaling in smooth muscle in a transgenic mouse model of PAH. American Journal of Physiology-Lung Cellular and Molecular Physiology. 292(6). L1556–L1563. 58 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact